This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Collier, K. Articles by Savage, P. Search for Related Content PubMed PubMed Citation Articles by Collier, K. Articles by Savage, P. Social Bookmarking                         What's this?

Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity

Department of Medical Oncology, Charing Cross Hospital, London W6 8RF

Cordula Schink, MD

Department of Medical Oncology, Charing Cross Hospital, London W6 8RF

Anna Mary Young, MRCP

Department of Medical Oncology, Charing Cross Hospital, London W6 8RF

Katharine How, MRPharmS

Pharmacy Department, Charing Cross Hospital, London W6 8RF

Michael Seckl, PhD FRCP

Department of Medical Oncology, Charing Cross Hospital, London W6 8RF

Philip Savage, PhD FRCP

Department of Medical Oncology, Charing Cross Hospital, London W6 8RF, philip.savage{at}imperial.nhs.uk

Objective. To review the experience of treatment with etoposide phosphate in patients with acute etoposide hypersensitivity treated in a large tertiary referral center hospital specializing in curable malignancies.

Case summaries. The cases of 6 patients with advanced malignancies who experienced acute etoposide hypersensitivity are documented. There were 3 male and 3 female patients and their ages ranged from 16 to 68. Four patients had curable malignancies with trophoblast tumors or germ cell tumors and two were receiving palliative chemotherapy for other malignancies. All of the 6 patients who experienced etoposide hypersensitivity developed their symptoms in the first few minutes of the initial infusion. The most common symptoms were chest pain, facial flushing, and bronchospasm. All of the patients had emergency treatment with discontinuation of the infusion and usually the administration of hydrocortisone and chlorpheniramine, which lead to the rapid resolution of their symptoms.

For the next cycle of chemotherapy each patient was rechallenged with etoposide phosphate, with steroid cover given in only two of the cases. None of the 6 patients experienced any hypersensitivity symptoms on treatment with etoposide phosphate and in one the steroids were withdrawn for all the subsequent cycles. The 4 patients with curable malignancies all remain disease free, while the 2 palliative patients obtained significant control of their disease.

Discussion. Etoposide is one of the most important chemotherapy drugs in the treatment of many curable malignancies but an acute hypersensitivity reaction occurs in around 1% of patients. Retreatment with etoposide in these patients is difficult and generally alternative drugs/regimens have to be used. A small number of case reports have suggested that etoposide phosphate can be safely used in these patients and 6 cases have been found in the pharmacy records where this has been done. In all of the patients, treatment with etoposide phosphate proceeded without any symptoms or the use of repeated steroid cover in 5 of the 6 patients.

Conclusion. Etoposide hypersensitivity is a rare clinical problem and responds promptly to drug discontinuation, steroids, and chlorpheniramine. Patients with previous etoposide hypersensitivity can safely be treated with etoposide phosphate and do not need any additional hypersensitivity prophylaxis. J Oncol Pharm Practice (2008) 14: 51—55.

Key Words: chemotherapy • hypersensitivity • etoposide • etoposide phosphate

Journal of Oncology Pharmacy Practice, Vol. 14, No. 1, 51-55 (2008)
DOI: 10.1177/1078155207085355


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?